Proton Pump Inhibitors Reduce the Size and Acidity of the Gastric Acid Pocket (Clin Gastroenterol Hepatol 2014;12:1101-1107, e1)

Jo, Yun Ju

doi:10.5056/jnm14152

Cited by 7 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This pocket may migrate into the esophagus and cause postprandial reflux symptoms. 74 While PPI use may alter the location or reduce the size of the pocket, 75 one of the only studies investigating this mechanism found no difference in location or pH of the acid pocket between PPI responders and partial responders. 21 …”

Section: Causes Of Refractory Gerdmentioning

confidence: 99%

Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions

Mermelstein¹,

Mermelstein²,

Chait³

2018

CEG

View full text Add to dashboard Cite

A significant percentage of patients with gastroesophageal reflux disease (GERD) will not respond to proton pump inhibitor (PPI) therapy. The causes of PPI-refractory GERD are numerous and diverse, and include adherence, persistent acid, functional disorders, nonacid reflux, and PPI bioavailability. The evaluation should start with a symptom assessment and may progress to imaging, endoscopy, and monitoring of esophageal pH, impedance, and bilirubin. There are a variety of pharmacologic and procedural interventions that should be selected based on the underlying mechanism of PPI failure. Pharmacologic treatments can include antacids, prokinetics, alginates, bile acid binders, reflux inhibitors, and antidepressants. Procedural options include laparoscopic fundoplication and LINX as well as endoscopic procedures, such as transoral incisionless fundoplication and Stretta. Several alternative and complementary treatments of possible benefit also exist.

show abstract

Section: Causes Of Refractory Gerdmentioning

confidence: 99%

Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions

Mermelstein¹,

Mermelstein²,

Chait³

2018

CEG

View full text Add to dashboard Cite

show abstract

“…Acid reflux is a normal physiological phenomenon that occurs in everyone, but it can cause GERD symptoms when unsuppressed acid refluxes into the esophagus. Acid pockets are areas of unrestrained gastric acid that accumulate in the proximal stomach after meals and may serve as a reservoir for acid reflux, especially in a large hiatal hernia [ 58 , 59 ]. Acid pockets develop due to inadequate support from food to release acid in the proximal part of the stomach, leading to reflux into the esophagus.…”

Section: Gastroesophageal Reflux Disease (Gerd)mentioning

confidence: 99%

“…New acid-suppressant drugs called PCABs act faster than PPIs, inhibit gastric H+K+ATPase, and are non-inferior in healing esophagitis [ 58 , 59 ]. P-CABs like vonoprazan and tegoprazan are prominent examples.…”

Section: Gastroesophageal Reflux Disease (Gerd)mentioning

confidence: 99%

“…Acid secretion pathway GERD development is closely linked to gastric acid production, which plays a central role. Proton Pump Inhibitors (PPIs) are commonly used to decrease acid production by inhibiting the H+/K+ ATPase pump in gastric parietal cells [58]. Acid reflux is a normal physiological phenomenon that occurs in everyone, but it can cause GERD symptoms when unsuppressed acid refluxes into the esophagus.…”

Section: Targeting Molecular Pathwaysmentioning

confidence: 99%

See 1 more Smart Citation

Chitosan Nanoparticles for Gastroesophageal Reflux Disease Treatment

Herdiana

2023

Polymers

View full text Add to dashboard Cite

Gastroesophageal Reflux Disease (GERD) is a chronic ailment that results from the backward flow of stomach acid into the esophagus, causing heartburn and acid regurgitation. This review explores nanotechnology as a novel treatment approach for GERD. Chitosan nanoparticles (CSNPs) offer several advantages, including biocompatibility, biodegradability, and targeted drug delivery capabilities. CSNPs have been extensively studied due to their ability to encapsulate and release medications in a controlled manner. Different nanoparticle (NP) delivery systems, including gels, microspheres, and coatings, have been developed to enhance drug retention, drug targeting, and controlled release in the esophagus. These nanoparticles can target specific molecular pathways associated with acid regulation, esophageal tissue protection, and inflammation modulation. However, the optimization of nanoparticle formulations faces challenges, including ensuring stability, scalability, and regulatory compliance. The future may see CSNPs combined with other treatments like proton pump inhibitors (PPIs) or mucosal protectants for a synergistic therapeutic approach. Thus, CSNPs provide exciting opportunities for novel GERD treatment strategies.

show abstract

An analysis of the biopharmaceutical behaviour of proton pump inhibitors with different physicochemical properties

et al. 2021

View full text Add to dashboard Cite

Proton Pump Inhibitors Reduce the Size and Acidity of the Gastric Acid Pocket (Clin Gastroenterol Hepatol 2014;12:1101-1107, e1)

Cited by 7 publications

References 11 publications

Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions

Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions

Chitosan Nanoparticles for Gastroesophageal Reflux Disease Treatment

An analysis of the biopharmaceutical behaviour of proton pump inhibitors with different physicochemical properties

Contact Info

Product

Resources

About